NeuroSense Research And Ddevelopement To Revenue from 2010 to 2025
| NRSNW Stock | USD 0.23 0.30 56.60% |
Research And Ddevelopement To Revenue | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check NeuroSense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuroSense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 214.9 K, Depreciation And Amortization of 117.1 K or Interest Expense of 379.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NeuroSense financial statements analysis is a perfect complement when working with NeuroSense Therapeutics Valuation or Volatility modules.
NeuroSense | Research And Ddevelopement To Revenue |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.